TWI865485B - 用於治療溶體儲積症相關的症狀和病症之方法(一) - Google Patents

用於治療溶體儲積症相關的症狀和病症之方法(一) Download PDF

Info

Publication number
TWI865485B
TWI865485B TW109103397A TW109103397A TWI865485B TW I865485 B TWI865485 B TW I865485B TW 109103397 A TW109103397 A TW 109103397A TW 109103397 A TW109103397 A TW 109103397A TW I865485 B TWI865485 B TW I865485B
Authority
TW
Taiwan
Prior art keywords
compound
weeks
alkoxy
pain
halogen
Prior art date
Application number
TW109103397A
Other languages
English (en)
Chinese (zh)
Other versions
TW202045167A (zh
Inventor
奈傑爾 克勞馥
泰雅 費雪
Original Assignee
美商健臻公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健臻公司 filed Critical 美商健臻公司
Publication of TW202045167A publication Critical patent/TW202045167A/zh
Application granted granted Critical
Publication of TWI865485B publication Critical patent/TWI865485B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109103397A 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法(一) TWI865485B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962800996P 2019-02-04 2019-02-04
US62/800,996 2019-02-04
US201962851433P 2019-05-22 2019-05-22
US62/851,433 2019-05-22
US201962894167P 2019-08-30 2019-08-30
US62/894,167 2019-08-30
US201962937618P 2019-11-19 2019-11-19
US62/937,618 2019-11-19
US202062962647P 2020-01-17 2020-01-17
US62/962,647 2020-01-17

Publications (2)

Publication Number Publication Date
TW202045167A TW202045167A (zh) 2020-12-16
TWI865485B true TWI865485B (zh) 2024-12-11

Family

ID=69743942

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109103397A TWI865485B (zh) 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法(一)
TW113119270A TW202508582A (zh) 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法(二)

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW113119270A TW202508582A (zh) 2019-02-04 2020-02-04 用於治療溶體儲積症相關的症狀和病症之方法(二)

Country Status (13)

Country Link
US (2) US20220016092A1 (cg-RX-API-DMAC7.html)
EP (2) EP3920913A1 (cg-RX-API-DMAC7.html)
JP (3) JP2022520747A (cg-RX-API-DMAC7.html)
KR (2) KR20210123352A (cg-RX-API-DMAC7.html)
CN (2) CN113645969A (cg-RX-API-DMAC7.html)
AU (2) AU2020217659B2 (cg-RX-API-DMAC7.html)
BR (2) BR112021015099A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128039A1 (cg-RX-API-DMAC7.html)
IL (3) IL313808B1 (cg-RX-API-DMAC7.html)
MX (2) MX2021009383A (cg-RX-API-DMAC7.html)
SG (2) SG11202107844UA (cg-RX-API-DMAC7.html)
TW (2) TWI865485B (cg-RX-API-DMAC7.html)
WO (2) WO2020163244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
PT3920912T (pt) 2019-02-04 2025-09-09 Genzyme Corp Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs)
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
IL300090A (en) 2020-07-24 2023-03-01 Genzyme Corp Pharmaceutical preparations containing VENGLUSTAT

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI546301B (zh) * 2011-03-18 2016-08-21 健臻公司 葡萄糖神經醯胺合成酶抑制劑

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (cg-RX-API-DMAC7.html) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
AU2012272815B2 (en) * 2011-06-22 2017-09-07 The General Hospital Corporation Treatment of proteinopathies
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI546301B (zh) * 2011-03-18 2016-08-21 健臻公司 葡萄糖神經醯胺合成酶抑制劑

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 MEHTA et al. Fabry disease: a review of current management strategies 2. An International Journal of Medicine 103(9) 2010 641-659 *

Also Published As

Publication number Publication date
TW202045168A (zh) 2020-12-16
MX2021009384A (es) 2021-09-10
CA3128041A1 (en) 2020-08-13
TW202508582A (zh) 2025-03-01
IL285304B1 (en) 2025-06-01
AU2020217659A1 (en) 2021-08-26
IL313808B1 (en) 2026-05-01
JP2022519274A (ja) 2022-03-22
SG11202107844UA (en) 2021-08-30
AU2020217659B2 (en) 2025-04-17
BR112021015099A2 (pt) 2021-10-05
TW202045167A (zh) 2020-12-16
SG11202107842QA (en) 2021-08-30
IL285304B2 (en) 2025-10-01
MX2021009383A (es) 2021-09-10
CA3128039A1 (en) 2020-08-13
IL285187B1 (en) 2026-06-01
US20220016092A1 (en) 2022-01-20
WO2020163245A1 (en) 2020-08-13
AU2020218496B2 (en) 2024-12-19
CN113710249A (zh) 2021-11-26
IL313808A (en) 2024-08-01
KR20210123352A (ko) 2021-10-13
KR20210123353A (ko) 2021-10-13
AU2020218496A1 (en) 2021-08-26
BR112021015172A2 (pt) 2021-09-28
US20220023273A1 (en) 2022-01-27
IL285187A (en) 2021-09-30
EP3920914A1 (en) 2021-12-15
JP7511567B2 (ja) 2024-07-05
JP2022520747A (ja) 2022-04-01
JP2025072556A (ja) 2025-05-09
WO2020163244A1 (en) 2020-08-13
CN113645969A (zh) 2021-11-12
EP3920913A1 (en) 2021-12-15
IL285304A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2021215396B2 (en) Methods for treating neurological symptoms associated with lysosomal storage diseases
JP2025072556A (ja) リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP7633169B2 (ja) グルコシルセラミドシンターゼ(gcs)阻害剤を使用した繊毛病の処置
CN107080747A (zh) 葡萄糖基神经酰胺合酶抑制剂
CN107872976A (zh) 用于治疗蛋白质病的方法
RU2829786C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
CA3128041C (en) Methods for treating symptoms and disorders associated with lysosomal storage diseases
RU2824599C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
RU2839414C1 (ru) Способы лечения неврологических симптомов, ассоциированных с лизосомными болезнями накопления